Indapta Therapeutics Secures 22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments
| FACTX Fund | USD 57.61 0.09 0.16% |
Slightly above 56% of Fidelity Advisor's investor base is looking to short. The analysis of overall sentiment of trading Fidelity Advisor Health mutual fund suggests that many investors are alarmed at this time. Fidelity Advisor's investing sentiment can be driven by a variety of factors including economic data, Fidelity Advisor's earnings reports, geopolitical events, and overall market trends.
Fidelity |
HOUSTON SEATTLE, December 17, 2024--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation cell therapies for the treatment of cancer and autoimmune diseases, announced today it has closed a 22.5 million round of new financing to accelerate the clinical development of its differentiated allogeneic Natural Killer cell therapy. Current investors RA Capital Management, LP, Leaps by Bayer, the impact investment arm of Bayer AG, Vertex Ven
Read at finance.yahoo.com
 |
Fidelity Advisor Fundamental Analysis
We analyze Fidelity Advisor's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fidelity Advisor using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fidelity Advisor based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
One Year Return
One Year Return Comparative Analysis
Fidelity Advisor is currently under evaluation in one year return among similar funds. One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
Fidelity Advisor Health Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fidelity Advisor mutual fund to make a market-neutral strategy. Peer analysis of Fidelity Advisor could also be used in its relative valuation, which is a method of valuing Fidelity Advisor by comparing valuation metrics with similar companies.
Peers
Fidelity Advisor Related Equities
| 70082LAB3 | 70082LAB3 | 2.51 | ||||
| FSELX | Fidelity Select | 0.95 | ||||
| FSCSX | Software | 0.78 | ||||
| MSTSX | Morningstar Unconstrained | 0.56 | ||||
| RRTLX | T Rowe | 0.25 | ||||
| LBHIX | Thrivent High | 0.24 | ||||
| VIASP | Via Renewables | 0.72 |
Other Information on Investing in Fidelity Mutual Fund
Fidelity Advisor financial ratios help investors to determine whether Fidelity Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fidelity with respect to the benefits of owning Fidelity Advisor security.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |